Intuitive Surgical revised its 2026 forecast for da Vinci robotic-surgery procedures, expecting growth closer to the…
Intuitive Surgical revised its 2026 forecast for da Vinci robotic-surgery procedures, expecting growth closer to the midpoint of its 14%-15% range, down from 13.5%-15.5%. Shares fell 7% in extended trading. Q3 revenue was $3.05B, beating estimates of $2.91B, with adjusted profit of $3 per share, above the $2.64 estimate. The company also announced plans for an Extended Use Program to reduce instrument costs.
How this was made
The 30-second read
Why it matters
The guidance downgrade signals slower adoption, which may lead to a re‑rating of the company's growth prospects.
Market read
Guidance revision caused a 7% share decline, indicating immediate trading relevance.
What to watch
Medicare and Medicaid policy changes could further influence procedure volumes beyond the guidance range.
Background
Intuitive Surgical provides the da Vinci robotic surgery platform; procedure growth drives recurring revenue from instruments and accessories.
Ticker impact
Intuitive Surgical tightened its 2026 da Vinci procedure growth forecast to the midpoint of 14%-15%, down from 13.5%-15.5%, and its shares fell about 7% in extended trading.
downward pressure as investors price in slower procedure growth
Guidance revision is a primary disclosure with a double‑digit same‑day move, indicating immediate market reaction.
Market effects
Potential slowdown in robotic‑surgery equipment demand may affect other med‑tech firms.
US market may see modest weakness in healthcare equipment stocks.
Limited to companies with exposure to robotic surgery technology.
Counterpoint
If the Extended Use Program successfully reduces instrument costs, the long‑term growth trajectory could remain strong despite the short‑term guidance cut.
Key entities
- CompanyIntuitive Surgical
Manufacturer of da Vinci robotic surgery systems.
